REGISTER
FOR TESTING

ACCESS REPORTS
REGISTER FOR TESTING
ACCESS REPORTS

Comprehensive Tumor Marker Testing for Early Cancer Detection

At MusB Diagnostics, our Tumor Marker Panel provides critical insights into cancer detection, monitoring, and treatment response. These specialized biomarkers help identify malignancies early, assess tumor progression, and evaluate the effectiveness of therapies, aiding in personalized cancer care and risk assessment.
99% accurate results within 24-72 hours
Early detection and monitoring of various cancers
Precision-driven testing for personalized treatment decisions

Tumor Markers for Comprehensive Cancer Screening

Alpha-Fetoprotein (AFP)
  • Used for liver cancer (hepatocellular carcinoma) and germ cell tumors
Carcinoembryonic Antigen (CEA)
  • Helps monitor colorectal, lung, breast, and pancreatic cancers
Breast Cancer Marker (CA 15-3 Antigen - BR Monitor)
  •  Specific for breast cancer progression and treatment response
Gastrointestinal Cancer Marker (CA 19-9 Antigen - GI Monitor)
  • Key marker for pancreatic, stomach, and bile duct cancers
Ovarian Cancer Marker (CA 125 Antigen - OV Monitor)
  • Assists in early detection and monitoring of ovarian cancer
Hybritech PSA (Prostate-Specific Antigen)
  • Standard prostate cancer marker for early detection and disease progression
Hybritech Free PSA
  • Differentiates between benign prostate conditions and cancer
Hybritech p2PSA
  • Enhances the accuracy of prostate cancer risk stratification

Advanced Cancer Monitoring for Better Outcomes

Early identification of cancer risks and progression
Comprehensive biomarker testing for targeted treatment
Accurate differentiation between benign and malignant conditions
Fast, reliable results for proactive patient management

MusB Diagnostics—delivering precision in cancer diagnostics for a healthier future.